JLSa2, founded in 2024, is a well‑resourced, seed‑stage venture backed company located in South San Francisco currently developing a robust pipeline of novel protein‑drug conjugate therapies to better address human metabolic diseases and other non‑oncology related diseases. The Senior Protein & Pept